Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Lumen Technologies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.03 (market cap $590.53M), while Lumen Technologies Inc trades at $6.49 (market cap $6.56B). The key difference: Lumen Technologies Inc is far larger — about 11.1× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | LUMN | |
|---|---|---|
Market Cap | $590.53M | $6.56B |
Sector | Health | Media |
52-Week High | $16.14 | $11.83 |
52-Week Low | $5.48 | $3.70 |
Enterprise Value | $627.78M | $18.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
LUMN trades at $6.45, down 4.16% today, reflecting ongoing investor caution amid a bearish technical signal. The company reported a net loss of $1.74 billion in 2025 despite beating earnings expectations in two of the last three quarters. Recent news highlights strategic moves like the Alkira acquisition to bolster its AI networking platform. Cash flow from operations remains strong at $4.74 billion, but high debt levels and negative profitability metrics pose challenges.
The outlook is mixed; cost-cutting and a $13 billion contract backlog offer potential upside, but persistent losses and a heavy debt load of $17.49 billion limit near-term growth. Analyst consensus is cautious with a hold-heavy rating, though the $8.25 price target implies modest upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
